Patents by Inventor Glenn M. Swartz
Glenn M. Swartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8153806Abstract: The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(?)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.Type: GrantFiled: July 16, 2010Date of Patent: April 10, 2012Assignee: The Children's Medical Center CorporationInventors: Anthony Treston, Jamshed H. Shah, Robert J. D'Amato, Kimberly A. Hunsucker, John Rougas, Barry P. Conner, Victor Pribdula, Glenn M. Swartz
-
Publication number: 20100280249Abstract: The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(?)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.Type: ApplicationFiled: July 16, 2010Publication date: November 4, 2010Inventors: Anthony Treston, Jamshed H. Shah, Robert J. D'Amato, Kimberly A. Hunsucker, John Rougas, Barry P. Conner, Victor Pribdula, Glenn M. Swartz
-
Patent number: 7812169Abstract: The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(?)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.Type: GrantFiled: November 30, 2001Date of Patent: October 12, 2010Assignee: The Children's Medical Center CorporationInventors: Anthony Treston, Jamshed H. Shah, Robert J. D'Amato, Kimberly A. Hunsucker, John Rougas, Barry P. Conner, Victor Pribdula, Glenn M. Swartz
-
Patent number: 7524865Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.Type: GrantFiled: July 21, 2004Date of Patent: April 28, 2009Assignee: Celgene CorporationInventors: Robert J. D'Amato, Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen
-
Publication number: 20080306113Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery.Type: ApplicationFiled: April 22, 2008Publication date: December 11, 2008Inventors: Anthony Treston, Jamshed H. Shah, Robert J. D'Amato, Kimberly A. Hunsucker, John Rougas, Barry P. Conner, Victor Pribdula, Glenn M. Swartz
-
Patent number: 7153867Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.Type: GrantFiled: August 6, 2002Date of Patent: December 26, 2006Assignee: Celgene CorporationInventors: Jamshed H. Shah, Barry P. Conner, Glenn M. Swartz, Kimberly A. Hunsucker, John Rougas, Robert J. D'Amato, Victor Pribluda, Anthony Treston
-
Patent number: 7112602Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(?)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.Type: GrantFiled: December 9, 2003Date of Patent: September 26, 2006Assignee: The Children's Medical Center CorporationInventors: Robert J. D'Amato, Shawn J. Green, John W. Madsen, William Fogler, Glenn M. Swartz, Jr., Adonia E. Papathanassiu, Jamshed H. Shah
-
Publication number: 20040147558Abstract: The invention provides new and useful analogs of 3-amino-thalidomide. These analogs include S(−)-3-amino-thalidomide and R(+)-3-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.Type: ApplicationFiled: March 11, 2004Publication date: July 29, 2004Inventors: Anthony Treston, Jamshed H Shah, Robert J D'Amato, Kimberly A Hunsucker, John Rougas, Barry P Conner, Victor Pribdula, Glenn M Swartz
-
Publication number: 20040127545Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R) (+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.Type: ApplicationFiled: December 9, 2003Publication date: July 1, 2004Applicant: Childrens' Medical CorporationInventors: Robert J. D'Amato, Shawn J. Green, John W. Madsen, William Fogler, Glenn M. Swartz, Adonia E. Papathanassiu, Jamshed H. Shah
-
Patent number: 6673828Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.Type: GrantFiled: May 11, 1999Date of Patent: January 6, 2004Assignee: Children's Medical Center CorporationInventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Adonia E. Papathanassiu, William Fogler
-
Publication number: 20030181428Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.Type: ApplicationFiled: October 15, 2002Publication date: September 25, 2003Inventors: Shawn J. Green, Glenn M. Swartz, Jamshed H. Shah, John Madsen, Robert J. D'Amato
-
Publication number: 20030139451Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.Type: ApplicationFiled: August 6, 2002Publication date: July 24, 2003Inventors: Jamshed H. Shah, Barry P. Conner, Glenn M. Swartz, Kimberly A. Hunsucker, John Rougas, Robert J. D'Amato, Victor Pribluda, Anthony Treston
-
Patent number: 6518298Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.Type: GrantFiled: February 20, 2001Date of Patent: February 11, 2003Assignee: Entremed, Inc.Inventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Robert J. D'Amato
-
Publication number: 20020018808Abstract: The present invention relates to immunoreactive compositions and methods for immunizing humans or animals against sterols, such as cholesterol and its derivatives, and their use in methods for reducing the serum cholesterol levels of the immunized individuals and to retard or reduce the severity of atherosclerosis or atherosclerosis plaques caused by ingestion of dietary cholesterol.Type: ApplicationFiled: May 1, 2001Publication date: February 14, 2002Inventors: Carl R. Alving, Julie Kenner, Glenn M. Swartz, John W. Madsen
-
Publication number: 20010012850Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.Type: ApplicationFiled: February 20, 2001Publication date: August 9, 2001Inventors: Shawn J. Green, Glenn M. Swartz, Jamshed H. Shah, John Madsen, Robert J. D'Amato
-
Patent number: 6228879Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprise the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.Type: GrantFiled: March 26, 1999Date of Patent: May 8, 2001Assignee: The Children's Medical CenterInventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Robert J. D'Amato
-
Patent number: 6224902Abstract: The present invention relates to immunoreactive vaccine compositions for immunizing humans or animals against sterols, such as cholesterol and its derivatives, and their use in methods for reducing the serum cholesterol levels of the immunized individuals and to retard or reduce the severity of artherosclerosis or artherosclerosis plaques caused by ingestion of dietary cholesterol.Type: GrantFiled: February 13, 1998Date of Patent: May 1, 2001Assignee: EntreMed, Inc.Inventors: Carl R. Alving, Julie Kenner, Glenn M. Swartz, Jr., John W. Madsen
-
Patent number: 5753260Abstract: The present invention relates to immunoreactive compositions and methods for immunizing humans or animals against sterols, such as cholesterol and its derivatives, and their use in methods for reducing the serum cholesterol levels of the immunized individuals and to retard or reduce the severity of atherosclerosis or atherosclerosis plaques caused by ingestion of dietary cholesterol. Another embodiment of the present invention encompasses ergosterol or ergosterol derivative compositions useful for the treatment or prevention of fungal infection, and methods of use thereof. Yet another aspect of the invention is dairy products containing anti-ergosterol antibodies produced by dairy animals immunized against ergosterol according to the present invention and methods of making thereof. A further aspect of the invention is a diagnostic assay for determining whether a human or animal has a fungal infection.Type: GrantFiled: April 14, 1995Date of Patent: May 19, 1998Assignee: EntreMed, Inc.Inventors: Carl R. Alving, Julie Kenner, Glenn M. Swartz, Jr., John W. Madsen
-
Patent number: 4885256Abstract: Monoclonal antibodies which demonstrate specific reactivity to cholesterol and methods for the detection of high levels of cholesterol by contacting biological specimens containing cholesterol with the monoclonal antibodies and measuring the formation of antigen-antibody complexes by immunosorbent assay.Type: GrantFiled: June 17, 1986Date of Patent: December 5, 1989Assignee: The United States of America as represented by the United States ArmyInventors: Carl R. Alving, Glenn M. Swartz, Jr.